What is Pravachol, and how does it work?

Pravachol is a prescription medicine used to treat the symptoms of high cholesterol, to lower blood levels of “bad” cholesterol (low-density lipoprotein or LDL), to increase levels of "good" cholesterol (high-density lipoprotein, or HDL) and to lower triglycerides. Pravachol may be used alone or with other medications.

Pravachol belongs to a class of drugs called Lipid-Lowering Agents, Statins, HMG-CoA Reductase Inhibitors.

It is not known if Pravachol is safe and effective in children younger than 8 years of age.

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

Prevention Of Cardiovascular Disease

In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), Pravachol (pravastatin sodium) is indicated to:

  • reduce the risk of myocardial infarction (MI).
  • reduce the risk of undergoing myocardial revascularization procedures.
  • reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes.

In patients with clinically evident CHD, Pravachol is indicated to:

  • reduce the risk of total mortality by reducing coronary death.
  • reduce the risk of MI.
  • reduce the risk of undergoing myocardial revascularization procedures.
  • reduce the risk of stroke and stroke/transient ischemic attack (TIA).
  • slow the progression of coronary atherosclerosis.

Hyperlipidemia

Pravachol is indicated:

  • as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1
  • as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV).  
  • for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet.
  • as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present:
    1. LDL-C remains ≥ 190 mg/dL or
    2. LDL-C remains ≥ 160 mg/dL and:
  • there is a positive family history of premature cardiovascular disease (CVD) or
  • two or more other CVD risk factors are present in the patient.

Limitations Of Use

Pravachol has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).

What are the side effects of Pravachol?

Pravachol may cause serious side effects including:

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Pravachol include:

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Pravachol. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

How to Lower Your Cholesterol & Save Your Heart See Slideshow

What is the dosage for Pravachol?

General Dosing Information

  • The patient should be placed on a standard cholesterol-lowering diet before receiving Pravachol and should continue on this diet during treatment with Pravachol.

Adult Patients

  • The recommended starting dose is 40 mg once daily. If a daily dose of 40 mg does not achieve desired cholesterol levels, 80 mg once daily is recommended.
  • Pravachol can be administered orally as a single dose at any time of the day, with or without food.
  • Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patient's response to therapy and established treatment guidelines.

Patients With Renal Impairment

  • In patients with severe renal impairment, a starting dose of 10 mg pravastatin daily is recommended.
  • Although the Pravachol 10 mg tablets are no longer available, pravastatin 10 mg tablets are available.

Pediatric Patients

Children (Ages 8 to 13 Years, Inclusive)
  • The recommended dose is 20 mg once daily in children 8 to 13 years of age.
  • Doses greater than 20 mg have not been studied in this patient population.
Adolescents (Ages 14 to 18 Years)
  • The recommended starting dose is 40 mg once daily in adolescents 14 to 18 years of age.
  • Doses greater than 40 mg have not been studied in this patient population.
  • Children and adolescents treated with pravastatin should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C.

Concomitant Lipid-Altering Therapy

  • Pravachol may be used with bile acid resins.
  • When administering a bile-acid-binding resin (e.g., cholestyramine, colestipol) and pravastatin, Pravachol should be given either 1 hour or more before or at least 4 hours following the resin.

Dosage In Patients Taking Cyclosporine

  • In patients taking immunosuppressive drugs such as cyclosporine concomitantly with pravastatin, therapy should begin with 10 mg of pravastatin sodium once-a-day at bedtime and titration to higher doses should be done with caution.
  • Most patients treated with this combination received a maximum pravastatin sodium dose of 20 mg/day.
  • In patients taking cyclosporine, therapy should be limited to 20 mg of pravastatin sodium once daily.
  • Although the Pravachol 10 mg tablets are no longer available, pravastatin 10 mg tablets are available.

Dosage In Patients Taking Clarithromycin

  • In patients taking clarithromycin, therapy should be limited to 40 mg of pravastatin sodium once daily.

What drugs interact with Pravachol?

For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases.

Cyclosporine

  • The risk of myopathy/rhabdomyolysis is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine.

Clarithromycin And Other Macrolide Antibiotics

  • The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin.
  • Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination.
  • Pravastatin should be used cautiously with macrolide antibiotics due to a potential increased risk of myopathies.

Colchicine

  • The risk of myopathy/rhabdomyolysis is increased with concomitant administration of colchicine.

Gemfibrozil

  • Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of Pravachol with gemfibrozil should be avoided.

Other Fibrates

  • Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, Pravachol should be administered with caution when used concomitantly with other fibrates.

Niacin

  • The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in Pravachol dosage should be considered in this setting.

Is Pravachol safe to use while pregnant or breastfeeding?

  • Pravachol is contraindicated for use in pregnant woman because of the potential for fetal harm. As safety in pregnant women has not been established and there is no apparent benefit to therapy with Pravachol during pregnancy, Pravachol should be immediately discontinued as soon as pregnancy is recognized.
  • Limited published data on the use of Pravachol in pregnant women are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage.
  • Pravastatin use is contraindicated during breastfeeding.
  • Based on one lactation study in published literature, pravastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production.
  • Because of the potential for serious adverse reactions in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with Pravachol.

QUESTION

What is cholesterol? See Answer

Summary

Pravachol is a prescription medicine used to treat the symptoms of high cholesterol, to lower blood levels of “bad” cholesterol (low-density lipoprotein or LDL), to increase levels of "good" cholesterol (high-density lipoprotein, or HDL) and to lower triglycerides. Pravachol may be used alone or with other medications. Pravachol belongs to a class of drugs called Lipid-Lowering Agents, Statins, HMG-CoA Reductase Inhibitors.

Treatment & Diagnosis

Medications & Supplements

Subscribe to MedicineNet's Heart Health Newsletter

By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 10/13/2020
References
FDA Prescribing Information
CONTINUE SCROLLING FOR RELATED SLIDESHOW